Summary: Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) frequently present with overlapping behavioral symptoms and identical genetic mutations, presenting a persistent diagnostic challenge for pediatric neurologists. Because traditional blood-based biomarkers are blocked or altered by the blood-brain barrier, clinical differentiation has historically relied on long-term behavioral tracking, which often delays vital early-intervention windows.
A new study demonstrated that a specialized carbon-fiber nanosensor can cleanly distinguish between ASD and ID by measuring real-time nitric oxide (NO) production in patient-derived stem cells. The bio-electrochemical approach utilizes induced pluripotent stem cells (iPSCs) to analyze molecular signaling at the earliest developmental stage.
The nanosensor detected vastly different, highly quantifiable nitric oxide baselines between the two conditions even when both patient cell lines carried the exact same genetic mutation, paving the way for definitive, objective precision diagnostics within the first few months of a child’s life.
Key Facts
- The Shared Mutation Breakthrough: The carbon-fiber nanosensor successfully distinguished ASD from ID cellular pathology even when the patient-derived cell lines shared the exact same genetic mutation profile.
- The Nitric Oxide Metrics: Real-time analysis revealed highly distinct, quantifiable NO concentrations across cohorts: ID patient cells generated $11text{ nM}$, ASD patient cells generated $6text{ nM}$, and healthy control cells produced a significantly higher baseline of $65text{ nM}$.
- Bypassing the Blood-Brain Barrier: By utilizing patient-derived iPSCs rather than peripheral blood tests, the diagnostic method completely sidesteps the blood-brain barrier, eliminating confounding factors like a patient’s age, dietary nutrition, or pharmaceutical treatments.
- Streamlined Workflow Efficiency: The testing protocol does not require scientists to differentiate the stem cells into mature neurons. High-resolution measurements were taken directly from undifferentiated iPSCs, significantly simplifying and accelerating the laboratory workflow.
- Infant Diagnostic Potential: While standard ASD diagnoses are delayed by waiting for behavioral milestones to manifest, this somatic stem-cell nanosensor approach could theoretically enable definitive differential testing within the first few months after birth.
- Precision Medicine Pathway: Though currently limited by initial sample sizes, the study establishes a scalable, objective laboratory template to apply precision biochemistry to complex neurodevelopmental disorders.
Source: KeAI Communications
A study published in NeuroMarkers showed that a nanosensor can measure nitric oxide (NO) from patient-derived stem cells to distinguish autism spectrum disorder (ASD) from intellectual disability (ID), even when both conditions share the exact same genetic mutation.
The researchers, from the Department of Chemistry and Biochemistry at Ohio University, used a carbon-fiber nanosensor, originally developed to study cardiovascular and Alzheimer’s disease to measure real-time NO production in induced pluripotent stem cells (iPSCs). The method bypasses the blood-brain barrier, which often makes blood-based biomarkers unreliable for brain conditions.
“ASD patient cells produced about 6 nM of NO, ID patient cells produced 11 nM, and healthy control cells produced 65 nM, a clear, quantifiable difference,” shares co-author Howard D. Dewald. “This is significant because ASD and ID often have overlapping symptoms and shared genetic causes, making early differential diagnosis difficult.”
“Despite overlapping etiologies and symptomatic similarities between autism and other neurodevelopmental disorders, real-time bio-electrochemical analysis of newly generated nitric oxide can still serve as a biomarker for the diagnosis and differential diagnosis of autism,” adds co-author Abdullah Asif Khan.
The duo chose iPSCs because they reflect the earliest developmental stage, eliminating confounding factors like age, nutrition, or drug treatments. “Surprisingly, the method did not require differentiating cells into neurons—measurements were made on undifferentiated iPSCs, simplifying the workflow,” notes Dewald.
Currently, ASD diagnosis relies on behavioral evaluations, which often delay identification. “This nanosensor-based approach could enable diagnosis in the first few months after birth using somatic cells,” says Khan.
While the study is limited by sample availability, it opens a new path for precision diagnostics in neurodevelopmental disorders.
Key Questions Answered:
A: Genetic tests look at the blueprint of a disease, but diseases don’t always express themselves identically. Even if an individual with Autism and an individual with an Intellectual Disability share the exact same genetic mutation, their cells may still behave differently. The carbon-fiber nanosensor looks past the blueprint to evaluate actual, real-time cellular behavior. By measuring the precise, nanomolar output of nitric oxide gas, the sensor uncovers a stark functional difference between the two conditions that remains entirely hidden on a genetic chart.
A: The brain is fiercely protected by the blood-brain barrier, which acts as a filter sorting what can enter and leave the central nervous system. Because of this filter, chemical flags in a patient’s blood rarely match the true, active chemistry inside the brain, rendering standard blood tests highly unreliable for neurodevelopmental conditions. By using induced pluripotent stem cells (iPSCs) grown from a patient’s own tissue, the researchers can watch brain chemistry unfold at its earliest developmental stage, completely free from the muddying effects of the blood barrier, patient age, diet, or medication.
A: Right now, diagnosing Autism or an Intellectual Disability is a waiting game. Doctors have to observe a child for months or years, tracking behavioral milestones, speech patterns, and social interactions, which often delays life-changing therapy until early childhood. This nanosensor technology could completely dismantle that delay. Because it operates on basic skin or somatic cells transformed into stem cells, a definitive, objective chemical diagnosis could be delivered within the first few months of a child’s life, allowing families to deploy targeted intervention programs years ahead of schedule.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurotech research news
Author: Ye He
Source: KeAi Communications
Contact: Ye He – KeAi Communications
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Nanosensor-based method for autism diagnosis using nitric oxide from patient-derived induced pluripotent stem cells as a biomarker” by Abdullah Asif Khan, Howard D. Dewald. NeuroMarkers
DOI:10.1016/j.neumar.2026.100166
Abstract
Nanosensor-based method for autism diagnosis using nitric oxide from patient-derived induced pluripotent stem cells as a biomarker
Objectives
The prevalence of autism spectrum disorder continues to increase worldwide, and diagnostic techniques and/or technologies are being developed to identify the disorder using biomarkers. Most biomarkers being studied do not address the differential diagnostic complexities that could arise from autism being caused by a mutation that may cause a different neurodevelopmental disorder (e.g., intellectual disability) in another individual.
The purpose of this study was to develop a differential diagnostic method in which the same causative mutation leads to autism in one patient but intellectual disability in the other, thereby validating the feasibility of neonatal nitric oxide as a biomarker for the differential diagnosis of autism.
Methods
Real-time bio-electroanalytical experiments were conducted using a porphyrinic modified carbon fiber-based nanosensor on induced pluripotent stem cells derived from an autism patient, a patient with intellectual disability, and a healthy individual to compare the levels of nascent nitric oxide among the samples. The choice of disease model cell lines was based on two factors: a) they must have the same causative mutation, and b) they should have different neuropsychiatric diagnoses.
The healthy control cell line had to be unrelated to the disease cell lines with no neuropsychiatric diagnosis for any neurodevelopmental or neurodegenerative disorder. Both autistic and intellectual disability patients had a rare de novo mutation (E198K) in the B56δ β-subunit of the protein phosphatase 2 A enzyme.
Results
An autistic individual may produce approximately half the amount (6 nM) of nitric oxide produced by an intellectual disability patient (11 nM) but approximately ten times less than that produced by a healthy individual (65 nM).
Conclusion
Despite overlapping etiologies and symptomatic similarities between autism and other neurodevelopmental disorders, real-time bio-electrochemical analysis of newly generated nitric oxide produced by induced pluripotent stem cells using carbon fiber-based porphyrinic nanosensors can still serve as a biomarker for the diagnosis and differential diagnosis of autism.
